71% Have Faced No Way To Dispose of Period Pads in Public Bathrooms, Study Reveals
New research from FLUUS revealed consumers have:
Hidden pads up their sleeves because of a lack of appropriate bins
Worn traditional pads for too long to the point they leaked, as they had nowhere to throw them away
Removed pads, wrapped them up and carried them around for hours
Put wrapped pads in their pocket and forgotten about them
LONDON, June 24, 2025 /PRNewswire/ -- We've all been there - feeling uncomfortable about how we navigate basic personal hygiene - but despite the advice against doing so - flushing pads is happening (an estimated 1.5M daily go down the toilet) - causing blocked pipes and microplastics to enter waterways.
Traditional pads take up to 500 years to biodegrade due to the plastic, glue, and absorbent polymers they contain, but 86% of people want flushable period products that solve the problem.
Aside from the flushing issue - 68% didn't realise period products often contain chemicals like PFAS and microplastics but Boots is leading the way, stocking FLUUS in 150 stores.
Inventor and Scientist Dr. Olivia Ahn wanted to create a better way, saying: "As a doctor, I've seen much research on the negative impact of microplastics on our health - they enter your body when you use the most common period care products. But no one is talking about microplastics in femcare because no one else has an alternative. At FLUUS, we do."
FLUUS is using pioneering Flushtec® technology, so pads fully disintegrate in water, leaving zero microplastics and zero landfill waste, with the equivalent of over 2 million plastic bags already diverted from landfill thanks to FLUUS customers.
59% would choose flushables when travelling, 33% want flushables for privacy especially in public environments, 86% of period product users want environmentally friendly, biodegradable alternatives and 46% would switch to flushable options to reduce their environmental footprint.
Dr. Ahn said: "Our period products shouldn't come with health warnings or disposal dilemmas. People are ready to make a small switch for a big impact. FLUSS isn't just a pad, it's proof you can have period care that truly puts your health and the planet first. We champion transparency and innovation, delivering a flushable and genuinely sustainable solution that respects your body, your convenience, and our planet."
FLUUS pads and liners are available at Boots.com and wearefluus.com:
FLUUS Liners (15 pack) – £3.49
FLUUS Winged Medium Pads (10 pack) – £3.99
Photo: https://mma.prnewswire.com/media/2717282/FLUUS.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/71-have-faced-no-way-to-dispose-of-period-pads-in-public-bathrooms-study-reveals-302489402.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
18 minutes ago
- Associated Press
Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients
SAN FRANCISCO, June 24, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc., a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced positive results from two Phase 2 clinical trials of PER-001, a novel therapeutic designed to address two leading causes of global blindness: glaucoma and diabetic retinopathy. Each of the six month, randomized, controlled trials evaluated PER-001, a first-in-class endothelin antagonist delivered in a slow-release, dissolvable implant that is injected into the back of the eye (intravitreal) every six months. Significant improvement in vision was demonstrated compared to control in each trial. With a therapy that targets the underlying cause of both diseases, early results of PER-001 show promise for transforming the trajectory of human blindness and offer evidence of PER-001's ability to reverse the course of progressive vision loss. The goal of this approach is to improve retinal blood flow and prevent the death of retinal cells that occur in ocular diseases. Ph2b/3 trials are planned to begin in the second half of 2025. 'Our goal is to pioneer the first disease-modifying treatment for ocular diseases that share a common underlying pathology of ischemia—starting with glaucoma and diabetic retinopathy and rapidly expanding into dry age-related macular degeneration,' said Phil Lai, MD, chief medical officer of Perfuse Therapeutics. 'Our studies demonstrated that PER-001 has the potential to transform care for leading causes of blindness, delivering sustained benefits that not only prevent blindness but also improve vision.' New Hope for Glaucoma Patients: Restoring Vision by Targeting the Root Cause Glaucoma is the leading cause of global blindness worldwide. An estimated 4.2 million people in the U.S. have glaucoma, but only about half are aware of their condition. Currently there are no glaucoma therapies approved by the U.S. Food and Drug Administration; treatments primarily consist of pharmacological, laser or surgical solutions to reduce intraocular pressure (IOP), which is normal in around half of glaucoma patients. Unfortunately, even with reduction of IOP, many patients progress to blindness. Key findings from the Phase 2a glaucoma trial showed that after single intravitreal administration of PER-001 released for six months, added to existing standard-of-care IOP-reducing therapies: 'Many people continue to have worsening glaucoma despite what is considered to be safe IOP. A holy grail in the treatment of glaucoma is the ability to reduce optic nerve damage by means other than lowering IOP,' said Joel Schuman, MD, professor and K.L. Roper Endowed Chair, Department of Ophthalmology at Wills Eye Hospital and president of Collaborative Community on Ophthalmic Innovation (CCOI). 'For the first time, Perfuse's Phase 2a glaucoma trial demonstrates neuroenhancement, improvement in the function of existing optic nerve tissue, in humans with glaucoma. Patients treated with PER-001 in this trial remarkably showed improvement in visual field performance, while those in the control group continued to deteriorate. The 7 dB scale of improvement in the Garway-Heath visual field sectors at a minimum of 5 testable points, is generally considered clinically significant and has been employed in the past by the U.S. Food and Drug Administration (FDA) as one criterion in considering approval of a new agent for glaucoma. In addition to enhancement of visual function, patients receiving PER-001 demonstrated improvements in ocular blood flow and optic nerve structure. Importantly, there is currently no FDA-approved drug for the treatment of glaucoma. The current study results are most encouraging, demonstrating the potential for a radically new, transformational treatment approach for this disease.' Improving Vision and Ischemia in Diabetic Retinopathy An estimated 9.6 million people in the U.S. are living with diabetic retinopathy, including more than 1.8 million with vision-threatening complications. Globally, diabetic retinopathy remains the leading cause of blindness among working age adults. Current treatment typically revolves around stabilization or improvement of a structural outcome, the Diabetic Retinopathy Severity Scale (DRSS), with no long-term benefit in vision. In many cases, peripheral vision is destroyed by laser treatment with hopes of maintaining central vision. Unfortunately, many patients continue to experience vision loss, even with available therapies. Key findings from the diabetic retinopathy Phase 2a trial showed a single intravitreal administration of PER-001 released for six months led to: Details of this phase are published in " PER-001, A Novel, Long Acting Endothelin Antagonist IVT Implant for the Treatment of Retinal Ischemia in Glaucoma, Diabetic Retinopathy and Age Related Macular Degeneration,' which was presented at Clinical Trials at the Summit (CTS) meeting on June 21. 'The results from the Ph2a study of PER-001 represent a major advancement in the treatment of diabetic retinopathy. For the first time, we're seeing a therapy for diabetic retinopathy that shows improvement in visual function,' said Arshad Khanani, MD, Clinical Professor of Ophthalmology at University of Nevada and Director of Clinical Research at Sierra Eye Associates, who presented the results at the CTS meeting. 'These functional gains in peripheral vision, contrast sensitivity and visual acuity accompanied by structural improvements in retinal ischemia, leakage, and microaneurysm validate the PER-001 mechanism of action. By targeting the endothelin pathway, PER-001 introduces a novel, every 6 months therapy, that can address the underlying neurovascular disease and offer vision benefits with the potential to be disease modifying for diabetic retinopathy and other ischemic retinal conditions.' A total of 60 patients were treated in both trials; 33 participants were enrolled in the glaucoma Ph1/2a and 27 participants in the diabetic retinopathy Ph2a study. The 24-week data demonstrated that PER-001 was safe and well-tolerated in both trials. With these encouraging results, Perfuse Therapeutics plans to initiate pivotal trials across both indications with a larger population of patients over a longer period, starting in the second half of 2025. About PER-001 PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma, diabetic retinopathy, age related macular degeneration and retinal vein occlusion. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. The PER-001 intravitreal implant is a bio-erodible implant administered into the vitreous cavity of the eye using a single-use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient dosing every six months. About Perfuse Therapeutics Perfuse Therapeutics is a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is developing a robust pipeline of novel assets against validated targets. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. For more information, visit and LinkedIn. Investor Relations and Media Contact [email protected]. View original content to download multimedia: SOURCE Perfuse Therapeutics
Business Wire
35 minutes ago
- Business Wire
Tivic Health Announces 2025 Annual Meeting of Stockholders
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questions for management's consideration through the virtual Annual Meeting platform both before and during the Annual Meeting. Only stockholders of record of shares of Tivic Health's common stock at the close of business on May 14, 2025 are entitled to notice of and to vote at, the Annual Meeting. To attend online and participate in the Annual Meeting, stockholders of record will need to use the control number included on the proxy card they received in the mail to log into the Annual Meeting. Beneficial owners who do not have a control number may gain access to the Annual Meeting by logging into their brokerage firm's website and selecting the stockholder communication mailbox to link through to the Annual Meeting. Instructions should also be provided on the voting instruction card provided by their broker, bank, or other nominee. The company's Proxy Statement, proxy card and Annual Report on Form 10-K for the year ended December 31, 2024, are available on the Internet at: SEC Filings - Tivic Health. About Tivic Health Systems, Inc. Tivic Health is a diversified immunotherapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health's bioelectronic program is focused on developing personalized non-invasive therapeutic devices for vagus nerve stimulation to improve clinical outcomes in inflammatory, neurologic and cardiac disease. The program also includes Tivic Health's first FDA approved product, ClearUP®, which has been proven to provide temporary relief of sinus pain, pressure and congestion and is available through top-tier online retail and distribution partners. The company's newly formed biopharmaceutical program is focused on commercial advancement of the toll-like receptor 5 drugs Entolimod™ and Entolasta™, including lead product candidate Entolimod for acute radiation syndrome. The company is also driving expansion into additional indications for Entolimod and Entolasta. For more information about Tivic Health, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors', as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
Yahoo
37 minutes ago
- Yahoo
Alivia Analytics Debuts Alivia 360™ Platform With Early Fraud, Waste, Abuse (FWA) Detection for Healthcare Payers
PHILADELPHIA, June 24, 2025 /PRNewswire/ -- Alivia Analytics, a leader in AI-powered FWA detection and analytics for healthcare payers, today announced the official debut of Alivia 360™, its unified platform for pre- and post-payment fraud, waste, and abuse (FWA) detection. As part of the launch, Alivia is introducing FWA Claims Manager™, a new pre-payment analytics solution that helps health plans and government agencies act earlier to prevent improper payments before they occur. FWA Claims Manager™ focuses on identifying high-risk providers and suspicious billing behavior that fall into the Gray Zone, subtle, often-overlooked activity between error, fraud, waste, and abuse that traditional rules-based systems fail to catch. By flagging these patterns before payment is issued, FWA Claims Manager enables earlier intervention, minimizes downstream effort, and protects plan resources. This advancement complements Alivia's established post-payment suite, where its AI-powered FWA Finder™ and centralized Alivia Case Manager™ continue to deliver value by detecting new leads, accelerating investigations, and streamlining fraud workflows. To further strengthen recovery outcomes, Alivia reinforces its post-pay payment integrity solutions, including Clinical Audits, Data Mining, and Code Editing. These capabilities help validate billing accuracy, medical necessity, and compliance across high-risk claims, driving greater audit precision and improved recoveries. "At a time when healthcare payers are under pressure to reduce losses and act faster, Alivia 360 provides one platform to detect and manage FWA from every angle," said Michael Taylor, MD, CEO of Alivia Analytics. "With the introduction of Early FWA Detection and expanded recovery analytics, we're equipping our clients with the tools to make smarter decisions across the entire claims lifecycle." Alivia 360™ also integrates proprietary data transformation services, enabling the rapid ingestion and standardization of fragmented claims data into analytics-ready formats, accelerating insights and driving operational impact across payer environments. About Alivia Analytics Alivia Analytics helps health plans and government agencies address complex claims challenges, combining AI-powered technology, expert services, and integrated analytics to reduce improper payments and recover more, faster. Our Alivia 360™ platform uncovers what rules-based systems miss, identifying hidden risks in the "Gray Zone" between error, fraud, waste, and abuse to deliver earlier detection and stronger results across the pre- and post-pay spectrum. Backed by data and IT transformation services, we help clients achieve faster results, greater savings, and reduced provider and member abrasion. View original content to download multimedia: SOURCE Alivia Analytics
